· Researchers state that post-vaccine syndrome is characterized by persistent immune dysregulation & issues with blood coagulation.
-
· Researchers state that post-vaccine syndrome is characterized by persistent immune dysregulation & issues with blood coagulation.
· A drug called dapagliflozin, used to treat Type 2 Diabetes, is being investigated for #LongCOVID in a clinical trial.
· A double-blind clinical trial is evaluating an experimental drug called REGN7544 for people with postural orthostatic tachycardia syndrome (POTS).
-
· Researchers state that post-vaccine syndrome is characterized by persistent immune dysregulation & issues with blood coagulation.
· A drug called dapagliflozin, used to treat Type 2 Diabetes, is being investigated for #LongCOVID in a clinical trial.
· A double-blind clinical trial is evaluating an experimental drug called REGN7544 for people with postural orthostatic tachycardia syndrome (POTS).
· The Bateman Horne Center and Open Medicine Foundation recently released a highly anticipated ME and Long COVID clinical care guide.
· Researchers estimate a higher rate of new-onset diabetes after SARS-C0V-2 infection in a systematic review in Emerging Microbes and Infections
· A new preprint in Medxriv further demonstrates that Long COVID and ME are not deconditioning.https://thesicktimes.org/2025/05/13/research-updates-may-13/
-
· The Bateman Horne Center and Open Medicine Foundation recently released a highly anticipated ME and Long COVID clinical care guide.
· Researchers estimate a higher rate of new-onset diabetes after SARS-C0V-2 infection in a systematic review in Emerging Microbes and Infections
· A new preprint in Medxriv further demonstrates that Long COVID and ME are not deconditioning.https://thesicktimes.org/2025/05/13/research-updates-may-13/
· #LongCOVID clinical trial assessing the monoclonal antibody AER002 found no difference between those who got the drug and placebo
· prospective study in Pediatric International found that, six months after SARS-C0V-2 infection, 23% of children had Long COVID symptoms
· Chinese study of five participants with Long COVID and myocarditis found severe damage in the mitochondria
https://thesicktimes.org/2025/05/20/research-updates-may-20/
-
· #LongCOVID clinical trial assessing the monoclonal antibody AER002 found no difference between those who got the drug and placebo
· prospective study in Pediatric International found that, six months after SARS-C0V-2 infection, 23% of children had Long COVID symptoms
· Chinese study of five participants with Long COVID and myocarditis found severe damage in the mitochondria
https://thesicktimes.org/2025/05/20/research-updates-may-20/
· A large study in Nature Genetics found a genetic risk factor for developing #LongCOVID
· Leading Long COVID and myalgic encephalomyelitis (ME) researchers have pushed back against an op-ed commissioned by the BMJ that spread false claims about #MECFS
· RECOVER-Treating Long COVID (TLC), the clinical trials initiative from the National Institutes of Health’s flagship Long COVID research program, shared updates about forthcoming trialshttps://thesicktimes.org/2025/05/27/research-updates-may-27/
-
· A large study in Nature Genetics found a genetic risk factor for developing #LongCOVID
· Leading Long COVID and myalgic encephalomyelitis (ME) researchers have pushed back against an op-ed commissioned by the BMJ that spread false claims about #MECFS
· RECOVER-Treating Long COVID (TLC), the clinical trials initiative from the National Institutes of Health’s flagship Long COVID research program, shared updates about forthcoming trialshttps://thesicktimes.org/2025/05/27/research-updates-may-27/
· New NIH study found that around one in seven children under age six with a prior SARS-CoV-2 infection met the probable diagnostic criteria for #LongCOVID
· Pemivibart (Pemgarda), a monoclonal antibody that helps prevent COVID-19, was found to be “well tolerated” and effective in phase 3 clinical trial
· New preprint from researchers in the US & Canada used a model called “Mobius” to classify ME & Long COVID with 97% accuracy, using data from bloodhttps://thesicktimes.org/2025/06/03/research-updates-june-3/
-
· New NIH study found that around one in seven children under age six with a prior SARS-CoV-2 infection met the probable diagnostic criteria for #LongCOVID
· Pemivibart (Pemgarda), a monoclonal antibody that helps prevent COVID-19, was found to be “well tolerated” and effective in phase 3 clinical trial
· New preprint from researchers in the US & Canada used a model called “Mobius” to classify ME & Long COVID with 97% accuracy, using data from bloodhttps://thesicktimes.org/2025/06/03/research-updates-june-3/
· Three recent studies show the harmful effects of misdiagnosis for chronic diseases and conditions
· A new preprint shared in Research Square found a connection between post-exertional malaise (PEM) and microclots, or tiny blood clots that disrupt how oxygen moves through the body
· The Cohen Center for Recovery from Complex Chronic Illness (CoRE) at Mount Sinai in New York is now recruiting for their rapamycin clinical trial for #LongCOVIDhttps://thesicktimes.org/2025/06/10/research-updates-june-10/
-
· Three recent studies show the harmful effects of misdiagnosis for chronic diseases and conditions
· A new preprint shared in Research Square found a connection between post-exertional malaise (PEM) and microclots, or tiny blood clots that disrupt how oxygen moves through the body
· The Cohen Center for Recovery from Complex Chronic Illness (CoRE) at Mount Sinai in New York is now recruiting for their rapamycin clinical trial for #LongCOVIDhttps://thesicktimes.org/2025/06/10/research-updates-june-10/
· Pregnant people infected with SARS-CoV-2 during first trimester more likely to have smaller newborns
· Children with multisystem inflammatory syndrome (MIS-C) triggered by COVID-19 had metabolic disturbances that “mirrored those seen in severe adult #COVID19 patients
· A population-level study from a database in Utah found there was a significant association between a past COVID-19 diagnosis and self-harming in children and adolescentshttps://thesicktimes.org/2025/06/17/research-updates-june-17/
-
· Pregnant people infected with SARS-CoV-2 during first trimester more likely to have smaller newborns
· Children with multisystem inflammatory syndrome (MIS-C) triggered by COVID-19 had metabolic disturbances that “mirrored those seen in severe adult #COVID19 patients
· A population-level study from a database in Utah found there was a significant association between a past COVID-19 diagnosis and self-harming in children and adolescentshttps://thesicktimes.org/2025/06/17/research-updates-june-17/
· A new review paper published in Psychiatry and Clinical Neurosciences focuses on how Long COVID impacts the nervous and immune systems
· Another study has found potential biomarkers in the blood of people with myalgic encephalomyelitis (ME)
· The Patient-Led Research Collaborative (PLRC) launched a new clinical trial and research study platform for Long COVID and associated diseases: the PLRC Registryhttps://thesicktimes.org/2025/06/24/research-updates-june-24/
-
· A new review paper published in Psychiatry and Clinical Neurosciences focuses on how Long COVID impacts the nervous and immune systems
· Another study has found potential biomarkers in the blood of people with myalgic encephalomyelitis (ME)
· The Patient-Led Research Collaborative (PLRC) launched a new clinical trial and research study platform for Long COVID and associated diseases: the PLRC Registryhttps://thesicktimes.org/2025/06/24/research-updates-june-24/
· Scientists found a new antiviral drug prototype that prevented Long COVID in mice and could also help treat the disease
· A recent preprint shared in medRxiv found further evidence of brain damage after COVID-19
· A new clinical trial for myalgic encephalomyelitis (ME) is recruiting in Tokyo, Japan, to test the monoclonal antibody Rituximabhttps://thesicktimes.org/2025/07/01/research-updates-july-1/
-
· Scientists found a new antiviral drug prototype that prevented Long COVID in mice and could also help treat the disease
· A recent preprint shared in medRxiv found further evidence of brain damage after COVID-19
· A new clinical trial for myalgic encephalomyelitis (ME) is recruiting in Tokyo, Japan, to test the monoclonal antibody Rituximabhttps://thesicktimes.org/2025/07/01/research-updates-july-1/
· The biotech company Invivyd, which makes the #COVID19 monoclonal antibody Pemgarda, announced that it has launched the SPEAR Study Group to explore the drug for #LongCOVID and post-vaccine syndrome (PVS)
· A new study from Taiwan published in Pediatrics and Neonatology found about 14% of children developed Long COVID after being infected with #SarsCoV2
· A new observational study is investigating the relationship between COVID-19 and #Diabeteshttps://thesicktimes.org/2025/07/08/research-updates-july-8/
-
· The biotech company Invivyd, which makes the #COVID19 monoclonal antibody Pemgarda, announced that it has launched the SPEAR Study Group to explore the drug for #LongCOVID and post-vaccine syndrome (PVS)
· A new study from Taiwan published in Pediatrics and Neonatology found about 14% of children developed Long COVID after being infected with #SarsCoV2
· A new observational study is investigating the relationship between COVID-19 and #Diabeteshttps://thesicktimes.org/2025/07/08/research-updates-july-8/
· A new study in PNAS found elevated oxidative stress was a shared characteristic in both #MECFS and #LongCOVID
· RECOVER-Treating Long COVID, the clinical trials initiative run by the Foundation for the NIAID, has announced that it will hold a second annual hybrid workshop discussing the initiative’s research
· A clinical trial in the U.K. called PHOSP-I is recruiting to test the monoclonal antibody Tocilizumabhttps://thesicktimes.org/2025/07/15/research-updates-july-15/
-
· A new study in PNAS found elevated oxidative stress was a shared characteristic in both #MECFS and #LongCOVID
· RECOVER-Treating Long COVID, the clinical trials initiative run by the Foundation for the NIAID, has announced that it will hold a second annual hybrid workshop discussing the initiative’s research
· A clinical trial in the U.K. called PHOSP-I is recruiting to test the monoclonal antibody Tocilizumabhttps://thesicktimes.org/2025/07/15/research-updates-july-15/
· A treatment for cats with a #COVID19-related infection may help advance #LongCOVID research
· The supplement Oxaloacetate may help reduce fatigue for LC, but it “did not reach statistical significance,” according to a new study at Bateman Horne Center
· A new prospective cohort study in JAMA Oncology of 1,572 participants with cancer found that COVID-19 had a “significant impact” on these patients, incl. hospitalization, treatment disruptions, death
Research updates, July 22 - The Sick Times
A treatment for cats with a COVID-related infection may help advance Long COVID research. In a small study in Stem Cells Translation Medicine, researchers treated 10 cats who got feline infectious peritonitis (FIP), a feline coronavirus infection that triggers immune dysfunction, and found that those who received a combination of the antiviral drug GS-441524 and mesenchymal stem/stromal cell (MSC) therapy had “enhanced immune recovery.”
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A treatment for cats with a #COVID19-related infection may help advance #LongCOVID research
· The supplement Oxaloacetate may help reduce fatigue for LC, but it “did not reach statistical significance,” according to a new study at Bateman Horne Center
· A new prospective cohort study in JAMA Oncology of 1,572 participants with cancer found that COVID-19 had a “significant impact” on these patients, incl. hospitalization, treatment disruptions, death
Research updates, July 22 - The Sick Times
A treatment for cats with a COVID-related infection may help advance Long COVID research. In a small study in Stem Cells Translation Medicine, researchers treated 10 cats who got feline infectious peritonitis (FIP), a feline coronavirus infection that triggers immune dysfunction, and found that those who received a combination of the antiviral drug GS-441524 and mesenchymal stem/stromal cell (MSC) therapy had “enhanced immune recovery.”
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· Two studies on potential biomarkers for #MECFS were published this month
· Stellate ganglion blocks, a procedure where an anesthetic is injected into nerves in the neck, may help reduce the severity of some symptoms of #LongCOVID and ME
· An observational study is recruiting 40 people in Boston, Massachusetts to test for defects of air and blood flow in the lungs in people with Long COVID
Research updates, July 29 - The Sick Times
Two studies on potential biomarkers for myalgic encephalomyelitis (ME) were published this month. Plus, new studies about stellate ganglion blocks.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· Two studies on potential biomarkers for #MECFS were published this month
· Stellate ganglion blocks, a procedure where an anesthetic is injected into nerves in the neck, may help reduce the severity of some symptoms of #LongCOVID and ME
· An observational study is recruiting 40 people in Boston, Massachusetts to test for defects of air and blood flow in the lungs in people with Long COVID
Research updates, July 29 - The Sick Times
Two studies on potential biomarkers for myalgic encephalomyelitis (ME) were published this month. Plus, new studies about stellate ganglion blocks.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children
· “Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames,” said one of the authors of a new study in Nature
· An upcoming at-home clinical trial program for #LongCOVID, run by Scripps Research, is seeking participants
Research updates, August 5 - The Sick Times
A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children, according to a new paper published in Science Translational Medicine.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children
· “Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames,” said one of the authors of a new study in Nature
· An upcoming at-home clinical trial program for #LongCOVID, run by Scripps Research, is seeking participants
Research updates, August 5 - The Sick Times
A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children, according to a new paper published in Science Translational Medicine.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· People with myalgic encephalomyelitis (#MECFS) have significant genetic differences in their DNA
· A very small clinical trial of the infusion drug BC 007 published in eClinicalMedicine found “significant improvement” in fatigue in people with #LongCOVID
· A phase 2 clinical trial testing the monoclonal antibody sipavibart is recruiting in Fort Lauderdale, Florida
Research updates, August 12 - The Sick Times
People with myalgic encephalomyelitis (ME) have significant genetic differences in their DNA, according to a preprint shared this week from the DecodeME study.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· People with myalgic encephalomyelitis (#MECFS) have significant genetic differences in their DNA
· A very small clinical trial of the infusion drug BC 007 published in eClinicalMedicine found “significant improvement” in fatigue in people with #LongCOVID
· A phase 2 clinical trial testing the monoclonal antibody sipavibart is recruiting in Fort Lauderdale, Florida
Research updates, August 12 - The Sick Times
People with myalgic encephalomyelitis (ME) have significant genetic differences in their DNA, according to a preprint shared this week from the DecodeME study.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A new preprint from the National Institutes of Health (NIH) RECOVER study found that #COVID19 reinfections may increase risk of #LongCOVID by about 35%
· A new review article in Ageing Research Reviews found that persistent infections from viruses, bacteria, fungus, and parasites can accelerate human aging
· A new Long COVID clinical trial to test the immunotherapy drug Anktiva was announced this week by the Chan Soon-Shiong Institute for Medicine
Research updates, August 19 - The Sick Times
A new preprint from the National Institutes of Health (NIH) RECOVER study found that COVID reinfections may increase the risk of Long COVID by about 35%.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A new preprint from the National Institutes of Health (NIH) RECOVER study found that #COVID19 reinfections may increase risk of #LongCOVID by about 35%
· A new review article in Ageing Research Reviews found that persistent infections from viruses, bacteria, fungus, and parasites can accelerate human aging
· A new Long COVID clinical trial to test the immunotherapy drug Anktiva was announced this week by the Chan Soon-Shiong Institute for Medicine
Research updates, August 19 - The Sick Times
A new preprint from the National Institutes of Health (NIH) RECOVER study found that COVID reinfections may increase the risk of Long COVID by about 35%.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· Metformin may help reduce the risk of #LongCOVID, according to two new studies
· A Phase 2 clinical trial is studying the drug vidofludimus calcium (IMU-838) for Long COVID
· The National Institutes of Health’s second RECOVER-Treating Long COVID workshop is happening next week, September 9–10
Research updates, September 2 - The Sick Times
Metformin may help reduce the risk of Long COVID, according to two new studies. One large study from the United Kingdom found that it reduced the rate of Long COVID in “obese and overweight” people by 63% percent.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· Metformin may help reduce the risk of #LongCOVID, according to two new studies
· A Phase 2 clinical trial is studying the drug vidofludimus calcium (IMU-838) for Long COVID
· The National Institutes of Health’s second RECOVER-Treating Long COVID workshop is happening next week, September 9–10
Research updates, September 2 - The Sick Times
Metformin may help reduce the risk of Long COVID, according to two new studies. One large study from the United Kingdom found that it reduced the rate of Long COVID in “obese and overweight” people by 63% percent.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A medium sized study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed #LongCOVID
· In a small case series, a combination of three antivirals was effective in improving symptoms in participants with Long COVID, according to a new preprint
· The Food and Drug Administration (FDA) accepted the drug application of a potential oral therapy for the prevention of #COVID19 following exposure
Research updates, September 9 - The Sick Times
A large study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed Long COVID. “This finding is consistent with the higher prevalence estimates reported globally and highlights the long-term burden of post-acute COVID-19 symptoms,” the authors of the study, published in BMC Infectious Diseases, wrote.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A medium sized study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed #LongCOVID
· In a small case series, a combination of three antivirals was effective in improving symptoms in participants with Long COVID, according to a new preprint
· The Food and Drug Administration (FDA) accepted the drug application of a potential oral therapy for the prevention of #COVID19 following exposure
Research updates, September 9 - The Sick Times
A large study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed Long COVID. “This finding is consistent with the higher prevalence estimates reported globally and highlights the long-term burden of post-acute COVID-19 symptoms,” the authors of the study, published in BMC Infectious Diseases, wrote.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced #LongCOVID, according to a new systematic review
· New funding will help advance a potential low-cost diagnostic test for myalgic encephalomyelitis (#ME)
· The SPEAR study group has proposed a potential Long COVID clinical trial with the company’s next-generation monoclonal antibody, VYD2311
Research updates, September 16 - The Sick Times
An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced Long COVID, according to a new systematic review that synthesized over 400 studies.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced #LongCOVID, according to a new systematic review
· New funding will help advance a potential low-cost diagnostic test for myalgic encephalomyelitis (#ME)
· The SPEAR study group has proposed a potential Long COVID clinical trial with the company’s next-generation monoclonal antibody, VYD2311
Research updates, September 16 - The Sick Times
An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced Long COVID, according to a new systematic review that synthesized over 400 studies.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· Two recent studies found limitations of the drug Paxlovid for protection from #LongCOVID, contrasting prior studies that suggested the antiviral drug might help prevent the disease
· Long COVID may increase menstrual bleeding, according to a new survey study published in Nature Communications
· A new clinical trial is testing the supplement Mitoquinone in combination with “exercise rehabilitation” (which may be detrimental) for Long COVID
Research updates, September 23 - The Sick Times
Two recent studies found limitations of the drug Paxlovid for protection from Long COVID, contrasting prior studies that suggested the antiviral drug might help prevent this disease.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
